Psychedelics Law

Policy and Advocacy

At Feldman Legal Advisors, we help shape the legal and regulatory frameworks that govern access to psychedelics, guided by a commitment to social justice, equity, and responsible reform. Effective advocacy and legislation can create lasting change, and we have a track record of delivering it.

Counsel Courtney Barnes was a lead drafter of Denver's Psilocybin Decriminalization Initiative, the nation's first successful voter-initiated psychedelic policy reform. It's one example of how we put deep policy expertise to work shaping law at the highest levels.

Colorado

At Feldman Legal Advisors, we guide individuals and organizations through Colorado's evolving psychedelics landscape. The 2022 Natural Medicine Health Act decriminalized possession of psilocybin, psilocin, mescaline, ibogaine, and DMT for adults 21 and older, and introduced a therapeutic access model that is reshaping mental health and wellness care.

Our deep understanding of this policy landscape lets us support service providers, facilitators, and other stakeholders navigating licensure under the NMHA — including Healing Center, Cultivation Facility, Products Manufacturer, Testing Facility, and Facilitator licenses. We also help out-of-state practitioners transition their practices to Colorado's regulatory environment.

Novel Compounds

At Feldman Legal Advisors, we work at the forefront of the shift psychedelic compounds are bringing to mental health treatment. Developing novel compounds means navigating a rigorous path guided by the FDA and DEA: organizing sponsors, conducting investigations, and completing multiple phases of clinical trials before final approval. It's a long road, with real potential for breakthrough therapies.

Our attorneys counsel entrepreneurs, researchers, and investors through this landscape, crafting strategies that foster innovation while ensuring compliance and managing risk. We're a dedicated partner through every phase of FDA approval, helping you move forward with confidence.